FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington. | D.C. | 20549 |
|-------------|------|-------|

| STATEMENT | OF | CHANGES | IN | BENEFICIAL | OWNERSHIP |
|-----------|----|----------------|----|-------------------|------------------|
| | | | | | |

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Jordt Raymond M</u> | | | | 2. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ALT] | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director | | | | | | |
|---|--|--|---|--|---|--------------------------|--------------------------------------|--|---|----------------------|---|---|---|---|---|---------------------------|-----|
| (Last) | , | irst) INC., 910 CLO | (Middle) PPER ROAI | D, | 3. Date of Earliest Transaction (Month/Day/Year) 01/25/2024 | | | | | X | X Officer (give title below) Other (specify below) Chief Business Officer | | | | | | |
| SUITE 201S | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | Line) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) | ERSBURG | MD | 20878 | | | | | | | | | X | | , | | ting Person One Report | - 1 |
| (City) | (S | tate) | (Zip) | | Rule | 10b5- | 1(c) | Transa | ctic | n Indi | ication | | | | | | |
| | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | o satisfy | | | | | | |
| | | Та | ble I - Non- | Deriva | ative S | ecuritie | s Ac | quired, D | isp | osed c | of, or Be | neficially | Owned | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/E | | | | Execution Date, | | Code (In | Transaction Disposed Of Code (Instr. | | ties Acquired (A) or I Of (D) (Instr. 3, 4 and 5 | | 5. Amount of Securities Beneficially Owned Following Reported | | Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | Code V Amount (A) or (D) | | | | Price | Transaction (Instr. 3 a | ion(s) | | | msu. 4) | | |
| | | | Table II - D (e | erivat e.g., pu | ive Se uts, ca | curities Ils, warr | Acq ants | uired, Dis s, options | spo | sed of, onverti | , or Bend ble secu | eficially (irities) | Owned | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Ye | Co | nsaction de (Instr. | saction Derivative Ex | | 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4) | | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) | | |
| | | | | Cod | de V | (A) | (D) | Date Exercisable | | piration ite | Title | Amount or Number of Shares | | (Instr. 4) | Jii(s) | | |
| Stock Options (option to buy) | \$9.28 | 01/25/2024 | | A | | 163,200 | | (1) | 01 | /25/2034 | Common Stock, par value \$0.0001 | 163,200 | \$0.00 | 163,20 | 0 | D | |
| Restricted Stock Units | (2) | 01/25/2024 | | A | | 58,400 | | (3) | | (3) | Common Stock, par value \$0.0001 | 58,400 | \$0.00 | 58,400 |) | D | |

Explanation of Responses:

- 1. Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date.
- 2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value \$0.0001, when vested.
- 3. The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

/s/ Richard Eisenstadt, as 01/29/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.